keyword
MENU ▼
Read by QxMD icon Read
search

III stage colon cancer

keyword
https://www.readbyqxmd.com/read/28818109/metastatic-colorectal-cancer-responsive-to-regorafenib-for-2-years-a-case-report
#1
Kenji Yoshino, Dai Manaka, Ryo Kudo, Shunpei Kanai, Eisei Mitsuoka, Satoshi Kanto, Shinya Hamasu, Sayuri Konishi, Ryuta Nishitai
BACKGROUND: Regorafenib is an oral multikinase inhibitor that has been demonstrated as clinically effective in patients with metastatic colorectal cancer in phase III studies. Although disease control was achieved in 40% of the pretreated patients with metastatic colorectal cancer in the pivotal studies, radiological response has rarely been reported. Severe adverse events associated with regorafenib are known to occur during the first and second courses of treatment. We present a case of a 62-year-old Japanese patient whose metastatic colorectal cancer has been responding to treatment with regorafenib for 2 years...
August 18, 2017: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/28812159/anatomical-and-embryological-perspectives-in-laparoscopic-complete-mesocoloic-excision-of-splenic-flexure-cancers
#2
Takeru Matsuda, Yasuo Sumi, Kimihiro Yamashita, Hiroshi Hasegawa, Masashi Yamamoto, Yoshiko Matsuda, Shingo Kanaji, Taro Oshikiri, Tetsu Nakamura, Satoshi Suzuki, Yoshihiro Kakeji
BACKGROUND: Laparoscopic complete mesocoloic excision (CME) with central vascular ligation for splenic flexure cancer is technically challenging because of its anatomical complexity. Although embryological and anatomical consideration should be helpful to perform CME in colorectal cancer surgery, such studies on the splenic flexure are lacking. METHODS: The splenic flexure is located embryologically between the terminal portion of the midgut and the beginning of the hindgut, and is supplied by the superior mesenteric and inferior mesenteric arteries...
August 15, 2017: Surgical Endoscopy
https://www.readbyqxmd.com/read/28805784/-short-term-outcomes-of-complete-mesocolic-excision-for-right-colon-cancer
#3
A O Rasulov, A G Malikhov, O A Rakhimov, N A Kozlov, O A Malikhova
PURPOSE: Complete mesocolic excision (CME) appears to be a relatively new concept for colon cancer. The purpose is to evaluate the results of CME with high vascular ligation (D3 lymph node dissection) for right colon cancer. The presented study identifies possible risks and advantages of the proposed method, as well as the role of the laparoscopic approach. MATERIAL AND METHODS: The article included data from 39 patients with right colon cancer, TNM stage I-III, operated on between November 2015 and December 2016 in the oncoproctology Department of the Blokhin Cancer Research Center...
2017: Khirurgiia
https://www.readbyqxmd.com/read/28801584/differences-of-protein-expression-profiles-kras-and-braf-mutation-and-prognosis-in-right-sided-colon-left-sided-colon-and-rectal-cancer
#4
Xian Hua Gao, Guan Yu Yu, Hai Feng Gong, Lian Jie Liu, Yi Xu, Li Qiang Hao, Peng Liu, Zhi Hong Liu, Chen Guang Bai, Wei Zhang
To compare protein expression levels, gene mutation and survival among Right-Sided Colon Cancer (RSCC), Left-Sided Colon Cancer (LSCC) and rectal cancer patients, 57 cases of RSCC, 87 LSCC and 145 rectal cancer patients were included retrospectively. Our results demonstrated significant differences existed among RSCC, LSCC and rectal cancer regarding tumor diameter, differentiation, invasion depth and TNM stage. No significant difference was identified in expression levels of MLH1, MSH2, MSH6, PMS2, β-Tubulin III, P53, Ki67 and TOPIIα, and gene mutation of KRAS and BRAF among three groups...
August 11, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28770104/immunoscore-in-mismatch-repair-proficient-and-deficient-colon-cancer
#5
Erkki-Ville Wirta, Toni Seppälä, Marjukka Friman, Juha Väyrynen, Maarit Ahtiainen, Hannu Kautiainen, Teijo Kuopio, Ilmo Kellokumpu, Jukka-Pekka Mecklin, Jan Böhm
The aim of this study was to investigate immune response and its prognostic significance in colon carcinomas using the previously described Immunoscore (IS). A population-based series of 779 colorectal cancers, operated on between 2000 and 2010, were classified according to tumour, node, metastasis (TNM) status, mismatch repair (MMR), and BRAF mutation status. Rectal cancer cases (n = 203) were excluded as a high proportion of these patients received preoperative neoadjuvant chemoradiotherapy. Tissue microarray (TMA) samples collected from the tumour centre and invasive front were immunostained for CD3 and CD8...
July 2017: Journal of Pathology. Clinical Research
https://www.readbyqxmd.com/read/28764863/cellular-expression-in-vitro-and-in-vivo-confirmation-of-gaec1-oncogenic-properties-in-colon-cancer
#6
Riajul Wahab, Vinod Gopalan, Farhadul Islam, Robert A Smith, Bin Qiao, Alfred K Lam
GAEC1 (Gene amplified in esophageal cancer 1) alterations have oncogenic properties in oesophageal squamous cell carcinomas and frequent amplifications of the gene were noted in colorectal adenocarcinomas. However, the subcellular localization and expression of GAEC1 at the protein level have never been reported in human cancer cells. The present study aimed to investigate whether GAEC1 is differentially expressed in different stages of colon cancer and to elucidate its underlying cellular and molecular mechanism in colon cancer progression...
July 26, 2017: European Journal of Cell Biology
https://www.readbyqxmd.com/read/28738943/presenting-stage-in-colon-cancer-is-associated-with-insurance-status
#7
David Lawrence, Lauren Weigel, Paul Dale, Betsy Smith, Michael D Honaker
Colorectal cancer continues to be the third most common cause of cancer death in the United States. Access to health care is also a nationwide problem. The purpose of the current study is to see if insurance status is associated with stage of colon cancer at presentation. The tumor registry was queried for all patients with colon cancer from 2009 to 2014. Demographics, including insurance status was statistically analyzed to determine if an association existed between insurance status and stage of colon cancer at the time of presentation...
July 1, 2017: American Surgeon
https://www.readbyqxmd.com/read/28717852/elevated-s100a8-protein-expression-in-breast-cancer-cells-and-breast-tumor-stroma-is-prognostic-of-poor-disease-outcome
#8
P Miller, K M Kidwell, D Thomas, M Sabel, J M Rae, D F Hayes, B I Hudson, D El-Ashry, M E Lippman
PURPOSE: Elevated S100A8 expression has been observed in cancers of the bladder, esophagus, colon, ovary, and breast. S100A8 is expressed by breast cancer cells as well as by infiltrating immune and myeloid cells. Here we investigate the association of elevated S100A8 protein expression in breast cancer cells and in breast tumor stroma with survival outcomes in a cohort of breast cancer patients. PATIENTS AND METHODS: Tissue microarrays (TMA) were constructed from breast cancer specimens from 417 patients with stage I-III breast cancer treated at the University of Michigan Comprehensive Cancer Center between 2004 and 2006...
July 17, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28714378/utilization-of-capecitabine-plus-oxaliplatin-and-5-fluorouracil-folinic-acid-plus-oxaliplatin-in-the-adjuvant-treatment-of-stage-iib-and-stage-iii-colon-cancer-a-multi-centre-retrospective-chart-review-study
#9
Aaron Sha, Shirin Abadi, Sharlene Gill
Purpose First, to assess drug utilization rates of capecitabine plus oxaliplatin (CAPOX) versus 5-fluorouracil plus oxaliplatin (mFOLFOX6) regimens in the treatment of stage IIB and stage III colon cancer. Second, to assess patient characteristics used to select CAPOX versus FOLFOX therapy, dose-limiting toxicities, dose intensities and treatment completion rates. Methods Patients with resected stage IIB or stage III colon cancer from five British Columbia Cancer Agency centres treated with CAPOX or mFOLFOX6 were selected for the analysis...
January 1, 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/28710725/clinicopathologic-parameters-associated-with-postoperative-complications-and-risk-factors-for-tumor-recurrence-and-mortality-after-tumor-resection-of-patients-with-colorectal-cancer
#10
Z Bai, J Wang, T Wang, Y Li, X Zhao, G Wu, Y Yang, W Deng, Z Zhang
OBJECTIVE: To delineate the association of postoperative complications with clinicopathologic factors and to identify risk factors for tumor recurrence and mortality after tumor resection in patients with colorectal cancer (CRC). METHODS: The clinical data of 1144 patients with CRC who underwent surgical intervention between 2003 and 2013 were retrieved. Correlations of postoperative complications with clinicopathologic factors were examined using univariate analysis...
July 14, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28706889/long-term-oncologic-outcomes-of-laparoscopic-surgery-for-splenic-flexure-colon-cancer-are-comparable-to-conventional-open-surgery
#11
Min Ki Kim, In Kyu Lee, Won-Kyung Kang, Hyeon-Min Cho, Bong-Hyeon Kye, Heba Essam Jalloun, Jun-Gi Kim
PURPOSE: Few studies about laparoscopic surgery for splenic flexure colon cancer have been published. This study aims to compare the short- and long-term outcomes of laparoscopic surgery for splenic flexure colon cancer with those of conventional open surgery. METHODS: From January 2004 to December 2010, 51 consecutive patients who underwent curative resection for stages I-III splenic flexure colon cancer were enrolled. Thirty-three patients underwent laparoscopy-assisted colectomy, while 18 patients underwent conventional open colectomy...
July 2017: Annals of Surgical Treatment and Research
https://www.readbyqxmd.com/read/28687025/prognostic-value-of-positron-emission-tomography-computed-tomography-for-adjuvant-chemotherapy-of-colon-cancer
#12
HyungJoo Baik, Seok Mo Lee, Sang Hyuk Seo, Min Sung An, Kwang Hee Kim, Ki Beom Bae, Min Kyung Oh, Kwan Hee Hong
BACKGROUND: To assess the prognostic value of preoperative (18) F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with high-risk stage II or stage III colon cancer who underwent FOLFOX chemotherapy. METHODS: The study included 166 patients with high-risk stage II or stage III colon cancer who received FOLFOX4 chemotherapy. Retrospective patient data were analysed including pathological stage, histology, disease-free survival (DFS) and the maximum standardized uptake value (SUVmax ) of the primary tumour on (18) F-fluorodeoxyglucose positron emission tomography/computed tomography...
July 7, 2017: ANZ Journal of Surgery
https://www.readbyqxmd.com/read/28669606/dose-response-effects-of-aerobic-exercise-among-colon-cancer-survivors-a-randomized-phase-ii-trial
#13
Justin C Brown, Andrea B Troxel, Bonnie Ky, Nevena Damjanov, Babette S Zemel, Michael R Rickels, Andrew D Rhim, Anil K Rustgi, Kerry S Courneya, Kathryn H Schmitz
BACKGROUND: Observational studies suggest that higher volumes of physical activity are associated with a lower risk of disease recurrence among survivors of colon cancer. However, the feasibility and safety of prescribing higher volumes of physical activity to survivors of colon cancer are unknown. Furthermore, the pathways through which exercise may reduce disease recurrence are unknown. PATIENTS AND METHODS: Survivors of stage I to III colon cancer were randomized to usual-care control, 150 minutes per week of aerobic exercise (low-dose), or 300 minutes per week of aerobic exercise (high-dose)...
June 17, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28651158/prospective-validation-of-a-lymphocyte-infiltration-prognostic-test-in-stage-iii-colon-cancer-patients-treated-with-adjuvant-folfox
#14
Jean-François Emile, Catherine Julié, Karine Le Malicot, Come Lepage, Josep Tabernero, Enrico Mini, Gunnar Folprecht, Jean-Luc Van Laethem, Stéphanie Dimet, Camille Boulagnon-Rombi, Marc-Antoine Allard, Frédérique Penault-Llorca, Jaafar Bennouna, Pierre Laurent-Puig, Julien Taieb
BACKGROUND: The prognostic value of lymphocyte infiltration (LI) of colorectal carcinoma (CC) has been demonstrated by several groups. However, no validated test is currently available for clinical practice. We previously described an automated and reproducible method for testing LI and aimed to validate it for clinical use. PATIENTS AND METHODS: According to National Institutes of Health criteria, we designed a prospective validation of this biomarker in patients included in the PETACC8 phase III study...
June 23, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28637568/disparities-in-the-age-related-rates-of-colorectal-cancer-in-the-united-states
#15
Emmanuel Gabriel, Katherine Ostapoff, Kristopher Attwood, Eisar Al-Sukhni, Patrick Boland, Steven Nurkin
The incidence of colorectal cancer (CRC) among Americans under the age of 50 years is increasing. The purpose of this study was to identify racial and socioeconomic disparities associated with this trend. The National Cancer Data Base was used to identify patients with CRC from 1998 to 2011. Patients were stratified by age (<50 versus >60 years), with ages 50 to 60 years omitted from the analysis to minimize overlapping trends between the two age groups. Relative frequencies (RFs) by year were plotted against demographic variables...
June 1, 2017: American Surgeon
https://www.readbyqxmd.com/read/28634730/phase-iii-trial-comparing-uft%C3%A2-%C3%A2-psk-to-uft%C3%A2-%C3%A2-lv-in-stage-iib-iii-colorectal-cancer-mcsgo-cctg
#16
Yasuhiro Miyake, Junichi Nishimura, Takeshi Kato, Masataka Ikeda, Masaki Tsujie, Taishi Hata, Ichiro Takemasa, Tsunekazu Mizushima, Hirofumi Yamamoto, Mitsugu Sekimoto, Riichiro Nezu, Yuichiro Doki, Masaki Mori
PURPOSE: Oral adjuvant uracil and tegafur plus leucovorin (UFT/LV) is not inferior to standard weekly fluorouracil and folinate for stage II/III colon cancer. However, protein-bound polysaccharide K (PSK) has been evaluated as postoperative adjuvant therapy for colorectal cancer. This report is the first of MCSGO-CCTG, which compared UFT/LV to UFT/PSK as adjuvant chemotherapy for stage IIB or III colorectal cancer in patients who had undergone Japanese D2/D3 lymph node dissection. METHODS: The primary endpoint was the 3-year disease-free survival (DFS)...
June 20, 2017: Surgery Today
https://www.readbyqxmd.com/read/28624221/mir-1290-is-a-biomarker-in-dna-mismatch-repair-deficient-colon-cancer-and-promotes-resistance-to-5-fluorouracil-by-directly-targeting-hmsh2
#17
Ling Ye, Tao Jiang, Huanzhang Shao, Lin Zhong, Zhaowen Wang, Yuan Liu, Huamei Tang, Bingyu Qin, Xiaoqing Zhang, Junwei Fan
5-Fluorouracil (5FU)-based adjuvant therapy is the first-line therapy for treating stage II and III colon cancer after surgery. However, its therapeutic efficacy is limited because of chemoresistance, especially in deficient mismatch repair (dMMR) colon cancer. Here, we first used laser capture microdissection to obtain purified cells from four dMMR and four proficient mismatch repair (pMMR) colon cancer tissues. Second, microRNA (miRNA) microarray chips were used to identify miRNAs that are differentially expressed between these two classes of tumors...
June 16, 2017: Molecular Therapy. Nucleic Acids
https://www.readbyqxmd.com/read/28622612/influence-of-age-and-comorbidity-on-prognosis-and-application-of-adjuvant-chemotherapy-in-elderly-japanese-patients-with-colorectal-cancer-a-retrospective-multicentre-study
#18
Tomoki Yamano, Shinichi Yamauchi, Kei Kimura, Akihito Babaya, Michiko Hamanaka, Masayoshi Kobayashi, Miki Fukumoto, Kiyoshi Tsukamoto, Masafumi Noda, Naohiro Tomita, Kenichi Sugihara
BACKGROUND: Adjuvant therapy for colorectal cancer (CRC) in patients aged ≥75 years is supported by inadequate evidence, although such patients are increasing in number worldwide. PATIENTS AND METHODS: We assessed the influence of age and comorbidities on the prognosis of CRC in elderly patients using pooled data by the Japanese Study Group for Postoperative Follow-up of Colorectal Cancer. In total, 4598 patients (3304 with colon cancer and 1294 with rectal cancer) who underwent curative surgery from 2004 to 2006 were analysed with respect to age, Charlson comorbidity score (CS), tumour marker positivity, adjuvant therapy and prognosis...
August 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28617898/mutation-in-braf-v600e-a-poor-prognostic-marker-in-stage-iii-colon-cancers-with-deficient-mmr
#19
Sheik Emambux, Guillaume Mouillet, David Tougeron
No abstract text is available yet for this article.
June 15, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28608229/erratum-to-preplanned-safety-analysis-of-the-jfmc37-0801-trial-a-randomized-phase-iii-study-of-six-months-versus-twelve-months-of-capecitabine-as-adjuvant-chemotherapy-for-stage-iii-colon-cancer
#20
Takeshi Suto, Megumi Ishiguro, Chikuma Hamada, Katsuyuki Kunieda, Hiroyuki Masuko, Ken Kondo, Hideyuki Ishida, Genichi Nishimura, Kazuaki Sasaki, Takayuki Morita, Shoichi Hazama, Koutarou Maeda, Hideyuki Mishima, Hideyuki Ike, Sotaro Sadahiro, Kenichi Sugihara, Masazumi Okajima, Shigetoyo Saji, Junichi Sakamoto, Naohiro Tomita
No abstract text is available yet for this article.
June 12, 2017: International Journal of Clinical Oncology
keyword
keyword
59219
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"